Edit

Pulmatrix Inc.

http://pulmatrix.com/

Last activity: 18.12.2021

Active

Categories: BioTechCareDeliveryDrugPlatformProductResearchTechnology

Pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. The platform, called iSPERSE (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. The iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.

Followers

2.09K

Mentions

Location: United States, Massachusetts, Lexington

Employees: 11-50

Total raised: $19.7M

Investors 4

Date	Name	Website
-	5AM Ventur...	5amventure...
17.07.2021	ARCH Ventu...	archventur...
06.11.2022	Hercules C...	htgc.com
-	Altitude L...	altitudels...

Funding Rounds 2

Date	Series	Amount	Investors
15.08.2011	-	$14M	-
14.12.2010	Grant	$5.7M	-

Mentions in press and media 22

Date	Title	Description
18.12.2021	Pulmatrix : Announces Closing of $6.75 Million Registered Direct Offering - Form 8-K	Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering LEXINGTON, Mass., December 17, 2021 /PRNewswire/ - Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical...
18.12.2021	Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering	LEXINGTON, Mass., Dec. 17, 2021 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmona...
16.12.2021	Pulmatrix : Announces $6.75 Million Registered Direct Offering - Form 8-K	Pulmatrix Announces $6.75 Million Registered Direct Offering LEXINGTON, Mass., December 15, 2021 (GLOBE NEWSWIRE) - Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical compan...
15.12.2021	Pulmatrix Announces $6.75 Million Registered Direct Offering	LEXINGTON, Mass., Dec. 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmona...
10.08.2021	Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update
27.07.2021	Pulmatrix appoints Director Anand Varadan
15.04.2021	Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine
12.04.2021	Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio
23.03.2021	Pulmatrix Reports 2020 Financial Results and Provides Business Update
04.03.2021	Pulmatrix Provides a Pipeline and Business Update
16.02.2021	Pulmatrix Announces Closing of $40 Million Registered Direct Offering
11.02.2021	Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
12.11.2020	Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates
21.10.2020	Pulmatrix Announces Commercial Launch of FEND, an OTC Nasal Hygiene Product Proven to Reduce Airborne Respiratory Droplets, with Partner Sensory Cloud
30.09.2020	Pulmatrix Announces Publication Demonstrating Reduction of Bioaerosols with FEND, an OTC Nasal Hygiene Product Designed to Cleanse Airways of Airborne Particles
29.09.2020	Pulmatrix Strengthens Board of Directors with Appointment of Todd Bazemore
17.03.2015	Ruthigen Merges with Pulmatrix	Ruthigen, Inc. (NASDAQ: RTGN), a biopharmaceutical company, merged with Pulmatrix, Inc., a Lexington, Massachusetts-based clinical stage biotechnology company. Pulmatrix will become a wholly-owned subsidiary of Ruthigen and all of its prior...
15.08.2011	Pulmatrix Secures $14M Series B1	Financing includes participation from all Pulmatrix's existing venture investors including Polaris Venture Partners, 5AM Ventures, Arch Venture Partners, and Novartis Venture Fund. >> Click here for more funding data on Pulmatrix ...
15.08.2011	PULMATRIX SECURES A $14 MILLION FINANCING TO ADVANCE CLINICAL PROGRAMS IN COPD AND CYSTIC FIBROSIS	-
15.08.2011	Pulmatrix Raises $14M in Series B1 Funding Round	Pulmatrix, a Lexington, MA-based clinical stage biotechnology company developing a new class of therapies for the prevention, treatment and control of respiratory diseases, has raised $14m in a Series B1 funding round. The financing, which ...
14.12.2010	Pulmatrix lands $5.7 million grant from Uncle Sam	Pulmatrix Inc. landed a $5.7 million contract from the Defense Advanced Research Projects Agency to develop a drug/device combination aimed at protecting military personnel and civilians against biological weapons. DARPA selected the Lexing...
02.11.2009	Pulmatrix Annunced $30.2M Equity Financing and $2.2M Grant from NIH	Pulmatrix, a Lexington, MA-based clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, has secured $30.2m in Series B eq...

Pulmatrix Inc.

Investors 4

Funding Rounds 2

Mentions in press and media 22

Reviews 0